Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Copy Top Investors Portfolio
Crypto Technical Analysis
Chart Pattern Signal

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ABBV
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
ABBV
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

ABBV Price Prediction Next Week

Based on the provided data and current market conditions, here's a comprehensive analysis for ABBV's price movement in the next trading week:

Technical Analysis:

The stock is currently showing bearish signals in the short term, with RSI at 40.07 indicating a neutral to slightly oversold condition. The stock closed at $171.56 on Friday, below its 20-day moving average of $176.62 and 200-day moving average of $177.12, suggesting downward pressure.

News Sentiment and Catalysts:

  1. Positive Developments:
  • AbbVie expanded its collaboration with AbCellera for oncology T-cell engagers development
  • The company received positive validation for Entresto patent from US Court of Appeals
  1. Challenges:
  • Recent $3.5 billion impairment charge related to emraclidine intangible asset from Cerevel acquisition
  • Increased competition in key therapeutic areas

Price Prediction for Next Week:

Target Prices:

  • Support Level: $167.43 (Fibonacci S2)
  • Resistance Level: $180.88 (Fibonacci R1)

Based on technical indicators and news sentiment:

  • Most Likely Scenario (60% probability): Stock will test support at $167-168 before bouncing back to $173-174
  • Bullish Scenario (25% probability): Break above $175 could push price to $180 resistance
  • Bearish Scenario (15% probability): Break below $167 support could lead to further decline to $162-163

Trading Recommendation: SELL Rationale:

  1. Technical indicators showing bearish momentum
  2. Trading below key moving averages
  3. Recent impairment charge may create short-term selling pressure
  4. Market uncertainty ahead of upcoming earnings season

Best entry for short positions: Current price ($171.56) Target exit: $167.50 Stop loss: $175.00

Based on the provided data and current market conditions, here's a comprehensive analysis for ABBV's price movement in the next trading week:

Technical Analysis:

The stock is currently showing bearish signals in the short term, with RSI at 40.07 indicating a neutral to slightly oversold condition. The stock closed at $171.56 on Friday, below its 20-day moving average of $176.62 and 200-day moving average of $177.12, suggesting downward pressure.

News Sentiment and Catalysts:

  1. Positive Developments:
  • AbbVie expanded its collaboration with AbCellera for oncology T-cell engagers development
  • The company received positive validation for Entresto patent from US Court of Appeals
  1. Challenges:
  • Recent $3.5 billion impairment charge related to emraclidine intangible asset from Cerevel acquisition
  • Increased competition in key therapeutic areas

Price Prediction for Next Week:

Target Prices:

  • Support Level: $167.43 (Fibonacci S2)
  • Resistance Level: $180.88 (Fibonacci R1)

Based on technical indicators and news sentiment:

  • Most Likely Scenario (60% probability): Stock will test support at $167-168 before bouncing back to $173-174
  • Bullish Scenario (25% probability): Break above $175 could push price to $180 resistance
  • Bearish Scenario (15% probability): Break below $167 support could lead to further decline to $162-163

Trading Recommendation: SELL Rationale:

  1. Technical indicators showing bearish momentum
  2. Trading below key moving averages
  3. Recent impairment charge may create short-term selling pressure
  4. Market uncertainty ahead of upcoming earnings season

Best entry for short positions: Current price ($171.56) Target exit: $167.50 Stop loss: $175.00

ABBV Similar Chart Price Prediction

The price of ABBV is predicted to go up 3.32%, based on the high correlation periods with PFSI. The similarity of these two price pattern on the periods is 90.65%.

stocks logo

ABBV

stocks logo

PFSI

Up: 3.32%Similarity: 90.65%

ABBV Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030

Year

ABBV Price Forecast($)

Potential Return(%)

2025

181.340

0.070

2026

216.000

19.190

2027

230.000

26.920

2028

230.000

26.920

2029

240.000

33.260

2030

250.000

38.810

What is ABBV stock price prediction 2025 ?

ABBV's stock price is currently $181.34. Based on its strong pipeline, including Skyrizi and Rinvoq, which are expected to surpass Humira's peak revenue by 2025, and its robust dividend growth, the stock could reach $210 by the end of 2025. This projection assumes continued revenue growth, successful drug launches, and stable market conditions.

What is ABBV stock price prediction 2026 ?

AbbVie's (ABBV) stock price in 2026 is projected to reach approximately $216, driven by strong growth from Skyrizi and Rinvoq, which are expected to surpass Humira's peak revenue by 2025. The company's robust pipeline, including advancements in oncology and neuroscience, supports long-term growth despite challenges like biosimilar competition. Valuation metrics, such as a forward P/E of 18, align with historical averages, indicating potential for steady appreciation.

What is ABBV stock price prediction 2027 ?

ABBV's stock price in 2027 is projected to reach approximately $230, driven by strong growth in its immunology drugs Skyrizi and Rinvoq, which are expected to generate over $27 billion annually by 2027. Additionally, AbbVie's diversified portfolio, including Botox and oncology drugs, supports consistent revenue growth despite Humira's decline. However, risks like competition and pipeline uncertainties could impact this forecast.

What is ABBV stock price prediction 2028 ?

ABBV's stock price in 2028 is projected to reach approximately $230, driven by strong growth in its immunology portfolio, particularly Skyrizi and Rinvoq, which are expected to generate over $27 billion in annual sales by 2027. Additionally, AbbVie's robust pipeline in neuroscience and oncology, alongside its consistent dividend growth, supports long-term valuation expansion. However, risks such as competition and execution challenges in acquisitions could moderate this growth trajectory.

What is ABBV stock price prediction 2029 ?

ABBV's stock price in 2029 is projected to reach approximately $240, driven by strong growth in its immunology drugs Skyrizi and Rinvoq, which are expected to generate over $27 billion annually by 2027. Additionally, its robust pipeline, including neuroscience and oncology developments, supports long-term revenue expansion. However, risks such as competition and execution challenges in acquisitions could impact this trajectory.

What is ABBV stock price prediction 2030 ?

ABBV's stock price in 2030 is projected to reach approximately $250, driven by strong growth in its immunology drugs Skyrizi and Rinvoq, which are expected to generate over $27 billion annually by 2027. Additionally, AbbVie's robust pipeline, including advancements in oncology and neuroscience, supports long-term revenue expansion. However, risks such as competition and execution challenges in acquisitions could impact this trajectory.

ABBV Revenue Forecast

ABBV EPS Forecast

ABBV FAQs

What is bull’s view on ABBV?

AbbVie (ABBV) is currently trading at $173, presenting a bullish opportunity with a 13.7% upside to the average analyst price target of $179.44. The growth is driven by strong performance in its immunology portfolio, particularly Skyrizi and Rinvoq, which are expected to surpass Humira's peak sales by 2025. Additionally, its 3.8% dividend yield and robust pipeline in neuroscience and oncology further solidify its long-term growth potential.

What is bear's view on ABBV?

ABBV stock is currently trading at $181.22, near its resistance level of $180.84. Bears argue that its high P/E ratio of 60 and reliance on Skyrizi and Rinvoq to offset Humira's declining sales pose risks if growth expectations falter. Additionally, competition in neuroscience and execution risks from recent acquisitions could pressure the stock below $172.26 support.

What is ABBV revenue forecast for next quarter？

The market consensus for ABBV's revenue in the upcoming quarter is projected to be approximately $13.266B USD.

What is ABBV eps forecast for next quarter？

The market consensus for ABBV's eps in the upcoming quarter is projected to be approximately $2.656 USD.

ABBV VS S&P500

AbbVie supports a strong dividend yield, which should act as valuation support, as the cash flows to support the dividend look secure over the next several years.

AbbVie's strong entrenchment in the aesthetics business (gained through the Allergan acquisition) sets up very long product cycles for several key assets like Botox based on strong brand power and physician entrenchment.

AbbVie's next generation immunology drugs targeting the IL23 and JAK pathways should help mitigate the competitive threats facing Humira over the next five years.

Ask Intellectia about ABBV

ABBV Analyst's Forecast

Srikripa Devarakonda

Truist Securities

Strong Buy

Price Target

$215 → $211

Upside

+18.66%

Truist analyst Srikripa Devarakonda lowered the firm's price target on AbbVie to $211 from $215 and keeps a Buy rating on the shares as part of a broader research note previewing FY25 for large-cap biopharma. The sector has underperformed the SP500, and with uncertainty around macro environment, investors have remained cautious, the analyst tells investors in a research note. Truist adds however that tailwinds for the sector could emerge from continued execution on launches, mid-stage growth, key catalysts, and an incoming administration potentially being more pro-pharma than expected. For the company, the firm is positive on its longer-term outlook as Humira erosion fades and Skyrizi/Rinvoq continue to gain momentum share across multiple indications, also citing share momentum behind Venclexta, Vraylar and migraine markets.
Christopher Raymond

Piper Sandler

Buy

Price Target

$212 → $220

Upside

+26.09%

Tim Anderson

B of A Securities

Hold

Price Target

$191

Upside

+8.38%

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2024 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free